Clinical Trial Update: Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) [Phase 2]

View source ↗

Summary

Phase 2 trial results assessing the safety, tolerability, and immunogenicity of an investigational recombinant human albumin (rHA)–based vaccine in children age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• Investigational vaccine with recombinant human albumin (rHA) (recombinant human albumin-based vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Measles, Mumps | Phase 2 | Status: COMPLETED